	US 12,391,698 B2
	Substituted piperidines and piperazines and methods for the treatment of CNS disorders
Ramakrishna Nirogi, Hyderabad (IN); Abdul Rasheed Mohammed, Hyderabad (IN); Anil Karbhari Shinde, Hyderabad (IN); Narsimha Bogaraju, Hyderabad (IN); Vinod Kumar Goyal, Hyderabad (IN); Santosh Kumar Pandey, Hyderabad (IN); Vijay Sidram Benade, Hyderabad (IN); Pradeep Jayarajan, Hyderabad (IN); Ramkumar Subramanian, Hyderabad (IN); and Venkateswarlu Jasti, Hyderabad (IN)
Assigned to SUVEN LIFE SCIENCES LIMITED, Hyderabad-Telangana (IN)
Appl. No. 18/721,449
Filed by SUVEN LIFE SCIENCES LIMITED, Hyderabad-Telangana (IN)
PCT Filed Jan. 11, 2023, PCT No. PCT/IB2023/050245 § 371(c)(1), (2) Date Jun. 18, 2024, PCT Pub. No. WO2023/135528, PCT Pub. Date Jul. 20, 2023.
Claims priority of application No. 202241001563 (IN), filed on Jan. 11, 2022.
Prior Publication US 2025/0092049 A1, Mar. 20, 2025
Int. Cl. A61K 31/4523 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01); A61P 25/00 (2006.01); A61P 25/14 (2006.01); A61P 25/28 (2006.01); C07D 241/04 (2006.01); C07D 401/14 (2006.01); C07D 487/04 (2006.01)

CPC C07D 487/04 (2013.01) [A61K 31/519 (2013.01); A61P 25/00 (2018.01); A61P 25/14 (2018.01); A61P 25/28 (2018.01)]

15 Claims

1. A compound of formula (I):

or a pharmaceutically acceptable salt or stereoisomer thereof,

wherein:

HetAr is:

X is H, halogen, or O(alkyl);

is the point of attachment to A;

A is CH or N;

P is —(CH₂)_b— or

Q is —CH₂—, —NH—, —N(alkyl)-, —N[C(O)R]—, —N[C(O)OR]—, or —O—;

R is alkyl, alkyl-O(alkyl), alkyl(aryl), or cycloalkyl;

b is 2, 3, 4, 5, or 6;

m is 0 or 1; and

n is 0 or 1;

with the provisos that:

(1) if Q is —CH₂—, then each B is independently H, halogen, or O(alkyl); and

(2) if Q is —NH—, —N(alkyl)-, —N[C(O)R]—, —N[C(O)OR]—, or —O—, then B is absent.

3. A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and the compound as claimed in claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof.